Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD

被引：36
|
作者：
De, Arka [1 ]
Bhagat, Naveen [1 ]
Mehta, Manu [1 ]
Taneja, Sunil [1 ]
Duseja, Ajay [1 ,2 ]
机构：
[1] Postgrad Inst Med Educ & Res, Dept Hepatol, Chandigarh, India
[2] Post Grad Inst Med Educ & Res, Dept Hepatol, Chandigarh 160012, India
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷 / 02期
关键词：
D O I：
10.1016/j.jhep.2023.07.031
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：e61 / e62
页数：2
相关论文
共 50 条
  • [1] Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    Abdelhameed, Farah
    Kite, Chris
    Lagojda, Lukasz
    Dallaway, Alexander
    Chatha, Kamaljit Kaur
    Chaggar, Surinderjeet S.
    Dalamaga, Maria
    Kassi, Eva
    Kyrou, Ioannis
    Randeva, Harpal S.
    [J]. CURRENT OBESITY REPORTS, 2024, 13 (03): : 510 - 531
  • [2] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03)
  • [3] Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Liu, Huan
    Yerevanian, Armen
    Westerhoff, Maria
    Hastings, Margaret H.
    Guerra, Justin Ralph Baldovino
    Zhao, Meng
    Svensson, Katrin J.
    Cai, Bishuang
    Soukas, Alexander A.
    Rosenzweig, Anthony
    [J]. DIABETES, 2024, 73 (02)
  • [4] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [5] Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease
    Behari, Jaideep
    Wang, Renwei
    Luu, Hung N.
    Mckenzie, David
    Molinari, Michele
    Yuan, Jian-Min
    [J]. HEPATOLOGY COMMUNICATIONS, 2024, 8 (07)
  • [6] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    [J]. LIFE-BASEL, 2024, 14 (07):
  • [7] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [8] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    [J]. JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
  • [9] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    [J]. DIABETES, 2024, 73
  • [10] Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients
    Dabbah, Shoham
    Ben Yakov, Gil
    Kaufmann, Monika-Inda
    Cohen-Ezra, Oranit
    Likhter, Maria
    Davidov, Yana
    Ben Ari, Ziv
    [J]. MINERVA GASTROENTEROLOGY, 2024, 70 (03): : 322 - 331
12345